BigHat Biosciences focuses on developing antibody therapies using machine learning and synthetic biology. Their main product is the Milliner platform, which integrates a synthetic biology lab with advanced machine learning to discover and engineer antibodies. This platform enables the rapid synthesis, purification, and characterization of numerous recombinant antibodies each week, allowing for quicker development of effective treatments for challenging diseases like certain infections and cancers. Unlike many competitors, BigHat emphasizes a balance between high performance and a family-friendly work culture. The company's goal is to create safer and more effective therapies for patients while maintaining a supportive work environment.

Bristol-Myers Squibb

GRIDS Capital

Gaingels

Quadrille Capital

Andreessen Horowitz

AME Cloud Ventures

Amgen Ventures

Section 32 Innovation Endeavors

AI & Machine Learning

Biotechnology

BigHat Biosciences

Strategic collaboration to leverage BigHat’s AI/ML (Artificial Intelligence / Machine Learning) guided Milliner™ platform to design high-quality next-generation protein therapeuticsSAN MATEO, Calif.--(BUSINESS WIRE)-- BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform announced a collaboration with Janssen Biotech Inc., a Johnson  Johnson company. This strategic collaboration combines the drug discovery, clinical development and data science expertise from Johnson  Johnson with BigHat’s Milliner™ platform, a suite of machine learning technologies integrated with a high-speed wet lab, to guide the design and selection for high-quality antibodies for multiple Neuroscience therapeutic targets. The agreement was facilitated by Johnson  Johnson Innovation.BigHat’s antibody design platform, Milliner™, integrates a synthetic biology-based high-speed wet lab with state-of-the-art machine learning technologies into a full-stack antibody discovery and engineering platform, to engineer antibodies with more complex functions and better biophysical properties. This approach reduces the difficulty of designing antibodies and other therapeutic proteins to tackle conditions ranging from chronic illness to life-threatening disease, while also massively speeding up candidate discovery and validation."We’re delighted to be collaborating with Johnson  Johnson to utilize BigHat’s Milliner™ platform to accelerate protein design," stated Mark DePristo, CEO and Co-founder of BigHat. “We look forward to fueling our shared goal of creating breakthrough therapies faster in difficult-to-treat diseases."About BigHat BiosciencesBigHat Biosciences designs safer, more effective biologic therapies for patients using machine learning and synthetic biology. BigHat integrates a wet lab for high-speed characterization with machine learning technologies to guide the search for better antibodies

Bighat Biosciences Enters Into Strategic Collaboration To Leverage Machine Learning In Antibody Discovery & Design

BigHat obtains access to Synaffix's site-specific ADC technology platform, and plans to combine Synaffix technology with its advanced ML antibody design platform to develop a new ADC pipeline

BigHat licenses Synaffix's site-specific ADC technology platform

The Danish company Adcendo and Chinese company Multitude Therapeutics entered into a $1 billion deal to develop ADCs for the treatment of cancer; and in August, the FDA lifted a partial hold on a Phase 1 trial evaluating an ADC candidate developed by MediLink Therapeutics and BioNTech for the treatment of advanced or metastatic non-small cell lung cancer and breast cancer.

Synaffix and BigHat Biosciences collaborate to develop AI-designed ADC

Similarly, AbbVie is collaborating with BigHat Biosciences to develop next-generation antibody therapeutics using the Milliner platform, focusing on oncology and neuroscience.

Billion-Dollar AI Deals Powering Antibody Design, Biologics, and Next-Gen Therapies

SAN MATEO, Calif.--(BUSINESS WIRE)--BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform announced a collaboration with Janssen Biotech Inc., a Johnson  Johnson company. This strategic collaboration combines the drug discovery, clinical development and data science expertise from Johnson  Johnson with BigHat’s Milliner™ platform, a suite of machine learning technologies integrated with a high-speed wet lab, to guide the design and selection for high-quality antibodies for multiple Neuroscience therapeutic targets. The agreement was facilitated by Johnson  Johnson Innovation. BigHat’s antibody design platform, Milliner™, integrates a synthetic biology-based high-speed wet lab with state-of-the-art machine learning technologies into a full-stack antibody discovery and engineering platform, to engineer antibodies with more complex functions and better biophysical properties. This approach reduces the difficulty of designing antibodies and other therapeutic proteins to tackle conditions ranging from chronic illness to life-threatening disease, while also massively speeding up candidate discovery and validation. "We’re delighted to be collaborating with Johnson  Johnson to utilize BigHat’s Milliner™ platform to accelerate protein design," stated Mark DePristo, CEO and Co-founder of BigHat

Bighat Biosciences Enters Into Strategic Collaboration To Leverage Machine Learning In Antibody Discovery  Design

PALO ALTO, Calif., Feb. 22, 2024 /PRNewswire/ -- S32, a leading venture capital firm founded by Bill Maris after building Google Ventures, today proudly announced the appointment of Dr. Andy Conrad, a leader in the application of technology and advanced data science, as General Partner. Dr. Conrad previously held numerous senior roles at Google, having most recently founded and served as the CEO and Executive Chairman of Verily Life Sciences (previously "Google Life Sciences"). He has held positions at GV ("Google Ventures") and X ("GoogleX"), and, during his tenure, worked with DeepMind, Google Cloud, Google AI and other technical and business teams across the Alphabet ecosystem

S32 Names Dr. Andy Conrad As General Partner

AbbVie Falls on Hookup with BigHat

(iStock / Getty Images Plus) While other biotechs are culling staff and programs to stay afloat, BigHat Biosciences has remained dry under its ever-expanding umbrella, announcing a multiprotein deal with Merck & Co. while growing its team 30% since the summer.

BigHat keeps dry amid stormy market, signs deal with Merck & Co.

SAN MATEO, Calif.--(BUSINESS WIRE)--BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, today announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company’s technology to design candidates for up to three drug discovery programs. BigHat’s design platform, Milliner, integrates a high-speed characterization with ML technologies to engineer antibodies with more complex functions and better biophysical properties. This approach could help reduce the difficulty of optimizing antibodies and other therapeutic proteins

Bighat Biosciences Announces Research Collaboration With Merck

San Mateo, CA – According to filings with the U.S. Securities and Exchange Commission, BigHat Biosciences is raising $80,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mark Depristo played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development. About BigHat Biosciences

San Mateo California Based Bighat Biosciences Is Raising $80,000,000.00 In New Equity Investment.

Develops antibody therapies using machine learning

BigHat Biosciences

Develops antibody therapies using machine learning

BigHat Biosciences

Develops antibody therapies using machine learning

About

Simplify's Take

What believers are saying

What critics are saying

What makes BigHat Biosciences unique

6 month growth

1 year growth

2 year growth

Recently Posted Jobs

BigHat Biosciences is Hiring for 0 Jobs on Simplify!